新疆喀什维吾尔族与汉族乳腺癌患者分子分型的研究  

Molecular subtypes of Uygur and Han patients with breast cancer in Kashgar, Xinjiang

作　　者：秦鑫添[1] 郝少欢[2] 塔来古丽.西仁白克 李玉齐[1] 古丽娜尔.阿不都拉 

机构地区：[1]广东药学院附属第一医院肿瘤内科,广州市510080 [2]喀什地区第一人民医院肿瘤内科

出　　处：《中国肿瘤临床》2014年第11期707-710,共4页Chinese Journal of Clinical Oncology

摘　　要：目的:比较维族与汉族乳腺癌患者分子分型特点,用以指导临床。方法:采用2011年《St.Gallen早期乳腺癌初始治疗国际专家共识》提出的乳腺癌分子分型方法对喀什地区第一人民医院369例有病理诊断的维、汉族乳腺癌患者进行分子分型,比较两者特点。结果:284例维族乳腺癌患者的Luminal A型、Luminal B伴HER-2阴性亚型、Luminal B伴HER-2阳性亚型、HER-2过表达型和三阴型乳腺癌比例分别为12.67%(36/284)、34.51%(98/284)、20.07%(57/284)、14.79%(42/284)和17.96%(51/284);85例汉族患者相应分子分型比例分别为16.47%(14/85)、37.65%(32/85)、10.59%(9/85)、10.59%(9/85)和24.71%(21/85);维族和汉族HER-2阳性率分别为34.86%(99/284)和21.18%(18/85);维族乳腺癌患者Luminal B伴HER-2阳性亚型比例高于汉族(P=0.045),维族乳腺癌患者HER-2阳性率高于汉族(P=0.030)。结论:与汉族患者比较,维族乳腺癌患者有较高的Luminal B伴HER-2阳性亚型比例和较高的HER-2阳性率,针对HER-2的靶向治疗在维族乳腺癌患者中显得更重要。Objective：This study aimed to compare the differences in molecular subtypes between Uygur and Han patients with breast cancer. This study was also conducted to provide clinical recommendations. Methods：The new typing standard of St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 was used to classify the molecular subtypes of 369 breast cancer cases from the First People＇s Hospital of Kashgar Prefecture, Xinjiang Uygur Autonomous Region, China. Four immunohistochemical markers （ER, PR, HER-2, and Ki-67） were used to divide the patients into four intrinsic subtypes：Luminal A;Luminal B （divided into HER-2 negative subtype and HER-2 positive subtype）;HER-2 enriched;and triple negative breast cancer （TNBC） subtype. Statistical analysis was then conducted to evaluate the differences in molecular subtype characteristics of Uygur and Han patients with breast cancer. Results：The proportion of Luminal A, Luminal B with HER-2 negative subtype, Luminal B with HER-2 positive subtype, HER-2 enriched, and TNBC subtype were 12.67%（36/284）, 34.51%（98/284）, 20.07%（57/284）, 14.79%（42/284）, and 17.96%（51/284） for 284 Uygur patients with breast cancer;the corresponding proportions were 16.47%（14/85）, 37.65%（32/85）, 10.59%（9/85）, 10.59%（9/85）, and 24.71%（21/85） for 85 Han patients with breast cancer, respectively. The HER-2 positive rates of Uygur and Han patients with breast cancer were 34.86%（99/284） and 21.18%（18/85）, respectively. The proportions of Luminal B with HER-2 positive subtype and HER-2 positive rate were significantly higher in Uygur patients than in Han patients （P=0.045 and P=0.030, respectively）.Conclusion：A larger proportion of Luminal B with HER-2 positive subtype and a higher HER-2 positive rate were observed in Uygur patients with breast cancer than in Han patients with the same disease. HER-2-targeted therapy could be more effective for Uygur patients with breast cancer than for Han patients.

关 键 词：乳腺肿瘤 组织学 免疫表型分型 少数民族 

分 类 号：R737.9[医药卫生—肿瘤]